Completed PHASE2 INTERVENTIONAL NCT00045812

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Interventions SCH-58235

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Mar 31, 2001 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00045812, this PHASE2 trial focuses on Lipoidosis and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States